n-CoDeR

Takeda's milestone payment strengthens BioInvent's business model

BioInvent strengthens its position as a partner in antibody development. This is clear after global pharmaceutical giant Takeda has now initiated...
BioInvent comments on the progress in the breast cancer study

BioInvent comments on progress in breast cancer study

BioInvent's pipeline consists of five drug candidates that are advancing...

Intervju
BioInvent achieves research milestone in partnership with Exelixis

BioInvent reaches research milestone in collaboration with Exelixis

BioInvent has reached a research milestone in its collaboration...

Intervju
BioInvent soon has five drug candidates in six clinical studies

BioInvent will soon have five drug candidates in six clinical studies

BioInvent has made a number of advances during the...
BioInvent's CFO on the company's business strategy

BioInvent's CFO on the company's business strategy

With a reported cash flow of just over 1,5 billion...

Intervju
BioInvent eventful 2023

BioInvent's CEO expects an eventful 2023

In 2022, the biotechnology company BioInvent demonstrated...

Intervju